Squarepoint
DNA icon

Squarepoint’s Ginkgo Bioworks DNA Stock Holding History

Squarepoint’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,013
Closed -$93.4K – 4182
2024
Q1 		$93.4K Buy
+2,013
New +$104K ﹤0.01% 3809

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $13.7B AUM 40.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
J.M. Forbes & Co
J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Squarepoint's DNA Position: Q3 2026 in Review

Squarepoint reduced its Ginkgo Bioworks (DNA) stake by 34% in Q3 2026, selling an estimated $43.8K and leaving 10,318 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #4166.

Squarepoint first reported a position in DNA in Q1 2022 and has held it in 13 quarters since. The position peaked at $1.94M in Q1 2023. 100 funds tracked by Wall St. Rank hold DNA as of Q3 2026.

  • Squarepoint held 10,318 shares of Ginkgo Bioworks worth $132K as of Q3 2026.
  • Squarepoint sold 5,371 Ginkgo Bioworks shares in Q3 2026, an estimated $43.8K.
  • Ginkgo Bioworks made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4166 holding.
  • Squarepoint first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 13 quarters since.
  • Squarepoint's Ginkgo Bioworks position peaked at $1.94M in Q1 2023.
  • 100 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.